<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987076</url>
  </required_header>
  <id_info>
    <org_study_id>P110108</org_study_id>
    <secondary_id>2012-001471-36</secondary_id>
    <nct_id>NCT01987076</nct_id>
  </id_info>
  <brief_title>Comparison Between Corticosteroid and Topical Steroids in the DRESS</brief_title>
  <acronym>DRESSCODE</acronym>
  <official_title>DRESS - Setting of Corticosteroid Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and severe multiorgan&#xD;
      adverse drug reaction occurring within 2 to 6-8 weeks after a new drug intake. DRESS syndrome&#xD;
      is defined by the combination of clinical manifestations, cutaneous, visceral and biological&#xD;
      disturbances. Its prognosis is directly linked to severity of visceral involvement, with a&#xD;
      mortality evaluated above 10%.&#xD;
&#xD;
      Considering curative treatment, there is no consensus. Until now, no controlled trial has&#xD;
      been performed. Systemic steroids are mainly used in first intention, in particular for&#xD;
      management of visceral involvements, whatever their severity. From clinical practice, topical&#xD;
      steroids are often used and could be helpful in the therapeutic management of DRESS.&#xD;
&#xD;
      We propose to evaluate systemic steroids versus very potent topical steroids in a&#xD;
      multicentric randomized controlled trial including defined moderate DRESS, ie the&#xD;
      non-inferiority of very potent topical steroids in terms of remission of visceral involvement&#xD;
      at Day30 and the superiority of very potent topical steroids in terms of delay to remission&#xD;
      of skin involvement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with a complete or almost healing of visceral involvement to D30 +/- 5 days AND complete or almost complete healing of skin involvement.</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with a complete or almost complete healing of cutaneous and visceral involvement at Day 30 ± 5 days</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delays of complete or almost complete visceral healing</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rates and bounces rates between the end of acute treatment and M12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients rate evaluating to severe form (occurrence of a criterion defining the severe form cf. Above)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence rate of moderate DRESS visceral involvement, during the initial treatment (D0 to D30) not existing at inclusion</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequelae rate at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic steroids adverse reactions rate</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topical steroids adverse reactions rate</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patch tests evaluation in DRESS</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactivation kinetics of Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Herpes Simplex virus (HSV), Human Herpes virus6 (HHV6) and Human Herpes virus7 (HHV7)</measure>
    <time_frame>Day 0, Day 7, Day 14, Day 21, Day 30, Month 3, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of lymphocyte transformation test in imputability</measure>
    <time_frame>Day 0, Day 30, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological factors evaluation in the skin</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood inflammatory cytokines and chemokines analysis</measure>
    <time_frame>Day 0, Day 30, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cytokines polymorphisms analysis</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Drug Rash With Eosinophilia and Systemic Symptoms</condition>
  <arm_group>
    <arm_group_label>Corticosteroids per os: Prednisone + Emollient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical corticosteroid: Clobetasol + Emollient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone:&#xD;
Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days.</description>
    <arm_group_label>Corticosteroids per os: Prednisone + Emollient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol</intervention_name>
    <description>Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week</description>
    <arm_group_label>Topical corticosteroid: Clobetasol + Emollient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient age ≥ 18 years&#xD;
&#xD;
          -  signing informed consent form&#xD;
&#xD;
          -  DRESS diagnosis with at least 4 criteria a, b, c, d&#xD;
&#xD;
               1. Skin rash occurring at least 10 days and not more than two months after&#xD;
                  continuous drug intake (or within less than 10 days in case of rechallenge)&#xD;
&#xD;
               2. Fever ≥ 38 ° at the time of examination or fever ≥ 38.5 ° peak in the last 72&#xD;
                  hours (amendment 2 : ANSM + CPP : 08/04/14)&#xD;
&#xD;
               3. at least one visceral compatible :&#xD;
&#xD;
          -  lymphadenopathy on at least two different sites measuring at least 1 cm in diameter&#xD;
&#xD;
          -  transaminases &gt; 2 upper limit of normal (ULN) or alkaline phosphatise &gt; 3 ULN&#xD;
&#xD;
          -  lung involvement defined by hypoxemia (capillary oximetry ≤ 95%) and/or interstitial&#xD;
             lung disease on chest radiography or scanner, in absence of other lung disease&#xD;
&#xD;
          -  myocarditis, pericarditis (ECG clinical suspicion and confirmed by echocardiography)&#xD;
&#xD;
          -  renal impairment defined as creatinine increase above the normal laboratory value&#xD;
             associated with leucocyturia &gt; 1000 / mm3 or proteinuria, a Na / K ratio &gt;1 and Urine&#xD;
             Cyto-bacteriology (EBCU) sterile in the absence of preexisting renal disease d) At&#xD;
             least one of the following haematological abnormalities:&#xD;
&#xD;
          -  eosinophilia ≥ 0.7 g/l or &gt; 10 % absolute&#xD;
&#xD;
          -  lymphocytosis ≥ 5*10^9 /l&#xD;
&#xD;
          -  presence of atypical blood lymphocytes&#xD;
&#xD;
          -  Patient with moderate DRESS : defined by at least one reached as follows :&#xD;
&#xD;
          -  pulmonary: interstitial pneumonia with oxygen partial pressure in arterial blood&#xD;
             (PaO2) 60-75 mmHg without dyspnoea at rest&#xD;
&#xD;
          -  Hepatic: transaminases ≥ 4 ULN and &lt; 15 ULN and/or PAL ≥5 ULN and V factor 50%&#xD;
             (amendment 2 : ANSM + CPP : 08/04/14)&#xD;
&#xD;
          -  renal :&#xD;
&#xD;
          -  acute renal failure and organic sharp increase in the 48 hours preceding the inclusion&#xD;
             of more of 26.4 micromol/l creatinine&#xD;
&#xD;
          -  and / or increase of 1.5 times the normal creatinine value&#xD;
&#xD;
          -  and / or decrease of oliguria of less than 0.5 ml/kg/h followed by a 6 hours&#xD;
&#xD;
          -  cord: pancytopenia (7≤Hb≤10 gr/dl and/or 50&lt;p&lt;100 G/L, 0.5&lt;PNN≤1.5G/l)&#xD;
&#xD;
          -  AND absence of cardiac, neurological or gastrointestinal (gut, pancreas) threatening&#xD;
&#xD;
          -  Drug withdrawal&#xD;
&#xD;
          -  Patient with health insurance (or entitled beneficiary)&#xD;
&#xD;
          -  Patient accepting the constraints of the test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled sepsis&#xD;
&#xD;
          -  unability to discontinue the medication(s) due&#xD;
&#xD;
          -  known hypersensitivity to systemic or topical corticosteroids&#xD;
&#xD;
          -  hepatitis B or C known, (active HIV status known suppressed by amendment 5 :&#xD;
             ANSM16/04/2015 and CPP 07/04/2015)&#xD;
&#xD;
          -  (Patient already treated by corticosteroid :&#xD;
&#xD;
               -  More than 48 hours&#xD;
&#xD;
               -  Less than 48 hours to following conditions :&#xD;
&#xD;
          -  Patients receiving more than 1 mg/kg/day of prednisone per os&#xD;
&#xD;
          -  Patients receiving methylprednisolone pulse up to 1mg/kg prednisone equivalent&#xD;
&#xD;
          -  (Patients receiving more than 30 grams per day level 3 topical steroid or more than 10&#xD;
             grams per day level 4 topical steroid --&gt; suppressed by amendment 3 : ANSM 28/05/14&#xD;
             CPP : 10/06/14)&#xD;
&#xD;
          -  (Patient undergoing immunosuppressive therapy for another disease suppressed by&#xD;
             amendment 5 : ANSM16/04/2015 and CPP 07/04/2015)&#xD;
&#xD;
          -  Participation in another drug biomedical research&#xD;
&#xD;
          -  Primitive bacterial infections, fungal or parasitic&#xD;
&#xD;
          -  Severe rosacea cont-indicating the use of corticosteroid&#xD;
&#xD;
          -  Presence of at least one ulcerated lesion (more than 10cm2)&#xD;
&#xD;
          -  Severe dermatitis perioral cont-indicating the use of corticosteroid&#xD;
&#xD;
          -  Severe acne contra-indicating the use of a corticosteroid&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CHOSIDOW, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier CHOSIDOW, MD, PhD</last_name>
    <phone>(0) 149812501</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.chosidow@hmn.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>: Laurence ALLANORE, MD</last_name>
    <phone>(0) 149812501</phone>
    <phone_ext>+33</phone_ext>
    <email>laurence.allanore@hmn.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHOSIDOW, MD, PhD</last_name>
      <phone>(0)149812501</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.chosidow@hmn.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laetitia GREGOIRE, M.Sc</last_name>
      <phone>(0)149814164</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.gregoire@hmn.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier CHOSIDOW, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, Guillot I, Paradis V, Joly P, Crickx B, Ranger-Rogez S, Descamps V. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009 Jan;145(1):67-72. doi: 10.1001/archderm.145.1.67.</citation>
    <PMID>19153346</PMID>
  </reference>
  <reference>
    <citation>Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, Beneton N, Jidar K, Barbaud A, Crickx B, Ranger-Rogez S, Descamps V. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. Eur J Dermatol. 2010 Jan-Feb;20(1):68-73. doi: 10.1684/ejd.2010.0821. Epub 2009 Oct 12.</citation>
    <PMID>19822481</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DRESS</keyword>
  <keyword>Systemic steroid</keyword>
  <keyword>Topical steroid</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Drug Hypersensitivity Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

